HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer

BACKGROUND: Trastuzumab emtansine (T-DM1) is approved for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (ABC), and has high efficacy. However, some patients exhibit primary resistance to T-DM1, and thus methods that can predict resista...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Breast Cancer
Autors principals: Sakai, Hitomi, Tsurutani, Junji, Iwasa, Tsutomu, Komoike, Yoshifumi, Sakai, Kazuko, Nishio, Kazuto, Nakagawa, Kazuhiko
Format: Artigo
Idioma:Inglês
Publicat: Springer Japan 2018
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6132843/
https://ncbi.nlm.nih.gov/pubmed/29700710
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12282-018-0861-9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars